Core Viewpoint - The company expects a significant net loss for the fiscal year 2025, with projections ranging from -75 million to -58 million yuan, indicating a year-on-year decline of 110.21% to 171.83% [1] Financial Performance - The anticipated net profit, excluding non-recurring gains and losses, is projected to be between -76 million and -59 million yuan, reflecting a year-on-year decrease of 109.10% to 169.34% [1] - The expected loss for the reporting period is between 58 million and 75 million yuan, with a decline in gross margin compared to the same period last year [1] Operational Challenges - The decline in performance is attributed to slight decreases in market prices for certain products, incomplete capacity release from newly established projects, and higher unit product costs [1] - The introduction of new products in 2025 has led to increased initial production costs [1] Strategic Focus - The company maintains a strategic focus on "innovation-driven development," increasing investment in new product research and development, enhancing the R&D management system, and deepening industry-academia-research collaboration, which has resulted in higher R&D expenses [1]
共同药业：预计2025年净利润同比下降110.21%-171.83%